# Zilucoplan (Zilbrysq)

> Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.

Source: https://peptides.cafe/peptide/zilucoplan
Category: Complement Inhibitor · Neuromuscular
Tag: FDA-Approved · Neuromuscular

## Mechanism
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.

## Research areas
- Generalized myasthenia gravis (anti-AChR antibody positive)

## Common research protocols
- Daily SC injection: Weight-based once-daily subcutaneous self-injection.

## Study summaries
- "RAISE phase 3 trial of zilucoplan in gMG" — Lancet Neurology (2023): Significant improvement in MG-ADL and QMG scores vs placebo at week 12.

## Considerations
- FDA-approved 2023.
- Requires meningococcal vaccination — risk of serious meningococcal infection.
- Injection-site reactions common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.